CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.
View all episodes
By BiotechTV
4.3
66 ratings
CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.
3,223 Listeners
1,917 Listeners
124 Listeners
325 Listeners
61 Listeners
9,948 Listeners
86 Listeners
33 Listeners
353 Listeners
19 Listeners
60 Listeners
510 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
48 Listeners